Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

disease to market our first blood diagnostic for the detection of AD and to continue our clinical research program with our compound EHT0202.

I am very confident in the efforts of our teams to obtain GBEA accreditation of our two GLPS service laboratories in molecular biology, both in Paris and in Gaithersburg, to serve biomedical research and our own medical diagnostics in neurodegenerative diseases and cancers. This is a crucial step for our revenues to grow as early as 2009. In addition, in 2008, we will have the results of over 5 years of ongoing efforts with our partners, Allergan and bioMerieux, and the new management will endeavour to translate these results in realistic operational and marketing ambitions."

Overview of ExonHit's business activities

In order to better organise its operations and to increase its chances of building its revenues, the Company has implemented two commercial departments: "Molecular Diagnostic/Genomic Services" and "Therapeutics".

Each department shall have the necessary resources to reach its objectives, as well as large autonomy to determine those objectives. The R&D, for each department, will conduct the research and reach the objectives that will have been set.

Of course, there will be the two departments will be connected and information shared. To this end, a Strategy department has been created, which aims at ensuring the coherence and the long term objectives of the Company. This department will include Operations and Project organisation.

For 2008, Operations will concentrate their efforts on obtaining an accreditation to realise clinical diagnostics in Paris and Gaithersburg. It will also realise the services which ExonHit offers its customers in biomedical research, and continue the promotion of its tools both in the US and in Europe.

In 2008, the Company will continue to invest in its two fields of activity, both in partnership and in-house, in line with the projects init
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... Safety, Proof of Mechanism of a Potential Oral Antagonist ... 20 Amira Pharmaceuticals, Inc., announced today the initiation ... internally discovered oral drug candidate for the treatment and ... arachidonic acid pathway.AM211 is an oral, selective antagonist of ...
... (Nasdaq: BNVI ) today announced the poster presentation ... compound and mechanism of action for its preclinical cancer drug ... conference of the American Association of Cancer Research (AACR) in ... , BN108, ...
... Group of AdvisorsSAN DIEGO, April 20 Trius Therapeutics, ... Board, naming Donald H. Batts, MD, FACP, FIDSA, and ... members of the group of anti-infective thought leaders. ... Michigan State University and the Chief of Infectious ...
Cached Biology Technology:Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2
(Date:7/11/2014)... and Mineral Research awarded Michael F. Holick, PhD, MD, ... 2014 Louis V. Avioli Award. Holick, a professor of ... for revolutionizing the understanding of vitamin D and its ... a member of the American Society for Bone and ... mineral basic research. It is named for ASBMR,s first ...
(Date:7/11/2014)... The Chinese University of Hong Kong, BGI and other ... to salt tolerance, with implication for improving this important ... online in Nature Communications provides an effective ... , Soybean is an important crop for the world. ... less genetic diversities than their wild counterparts. Among the ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... PITTSBURGH, Jan. 3 Mice bred to age too quickly ... scientists at the University of Pittsburgh School of Medicine injected ... of young, healthy animals. Instead of becoming infirm and dying ... cells improved their health and lived two to three times ...
... line of attack against pancreatitis and pancreatic cancer is ... substantial new funding from the Medical Research Council (MRC). ... digestion turn on the pancreas itself. Chronic pancreatitis increases ... five-year survival rate of all common cancers in the ...
... kind, researchers at Queens College and Mount Sinai School ... and maternal gestational diabetes together may cause a 14-fold ... six year olds. The data are published in the ... Adolescent Medicine , one of the JAMA/Archives journals. ...
Cached Biology News:Pitt: A shot of young stem cells made rapidly aging mice live longer and healthier 2New stage in fighting pancreatic cancer 2Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2
... pump, available in a single and twin head, ... design. With the most compact, lightweight package in ... in portable air and gas applications., Available ... T2-01TH). , Delivers 1.5 and 2.0 liters per ...
... for the mechanical harvesting of cells • ... even contact with the growth surface • ... flasks • Individually wrapped • Sterilized by ... CLS number is a new product number, ...
... The Yeast ProtoArray high-density functional protein microarray ... rapid elucidation of proteinprotein interactions on a ... S. cerevisiae open reading frames (ORFs) expressed ... duplicate on a 1 inch x 3 ...
... Yeast nitrogen base (YNB) is a base medium ... media. YNB contains ammonium sulfate but does not ... pouches are available. Each pouch contains reagents ... Pichia media or 1000 ml of 10X YNB ...
Biology Products: